Oncolytic viruses are attracting increasing attention for cancer therapy because of their potential to selectively infect and kill tumour cells, while leaving normal tissues largely unaffected. Such specificity is particularly important for intracranial tumours because the price of collateral damage is high. One virus of interest is myxoma virus (MYXV), a poxvirus that causes lethal disease in rabbits, but is non-pathogenic in all other species tested (Kerr & McFadden, 2002) . Myxoma virus has oncolytic effects on certain types of human cancer cells (Sypula et al., 2004) including glioma cells, making it a candidate for the treatment of brain tumours. In combination with rapamycin treatment, myxoma virus can improve the survival of immunocompetent rats bearing established intracranial gliomas without any obvious adverse effects on the animal or indications of infection outside of the tumour (Lun et al., 2010) . However, neurological symptoms may be difficult to detect using a rodent model and the infection of normal brain tissue could be a concern in clinical trials.
MYXV-Red is a recombinant myxoma virus derived from the Lausanne strain that expresses tdTomato red protein under the control of a synthetic vaccinia virus early/late promoter, and was originally designated vMyx-tdTr (Liu et al., 2009) . In studies involving intracranial injections of MYXV-Red to evaluate the therapeutic effect on brain tumours, we noticed occasional red ependymal cells when the needle track passed near the lateral ventricle (Fig. 1a) . We subsequently injected non-tumour bearing mice with MYXV-Red stereotaxically directed into the lateral ventricle of the brain. We then determined histologically the extent and duration of viral protein expression in brain tissue and characterized a small subset of cells that are transiently permissive to myxoma virus protein expression.
Virus replicated in RK13 cells was sucrose pad-purified prior to use in mouse experiments. C57BL/6 mice were infused with MYXV-Red (2610 6 p.f.u. in 0.8 ml) or PBS stereotaxically directed into the right lateral ventricle, and then sacrificed at 2 (n53), 4 (n53) or 11 days (n54) after virus inoculation. All procedures were approved by the Institutional Animal Care and Use Committee of the University of Illinois. Mice were perfused with formalin, brain tissue was extracted, and 10 mm sections were cut in a horizontal orientation through the extent of the lateral ventricles. Slides were stained with DAPI or haematoxylin/ eosin (H&E) and analysed using an Olympus microscope. tdTomato red expression was clearly visible in all mice 2 and 4 days following injection of MYXV-Red. The greatest number of ependymal and subventricular cells positive for tdTomato red expression was observed around both the right and left ventricle at 2 days following MYXV-Red inoculation (Fig. 1d) . By day 4, the number of red cells had decreased (Fig. 1e) , and by day 11 red cells were not observed, only scattered less intense red particles that may represent partially degraded tdTomato (Fig. 1f) .
Since the anti-tumour effects of MYXV are enhanced by concurrent rapamycin treatment (Stanford et al., 2007) , we determined whether the same pattern of tdTomato red expression would be observed in rapamycin-treated mice. A second cohort of mice (n53 for each time point) was injected with MYXV-Red as above, but treated with intraperitoneal injections of the drug rapamycin (3 mg kg
21
) concurrently with viral infusion and then every other day until euthanasia. Rapamycin has been shown to enhance MYXV replication and spread in cancer cells, possibly by further activating Akt, by counteracting the type I interferon response to the infection, or by limiting the number of infiltrating inflammatory cells in the tumour area (Lun et al., 2010) . We found that rapamycin increased the number of ependymal cells expressing tdTomato protein compared with mice that did not receive rapamycin (Fig. 1b , g-i compared to Fig. 1d-f ). However, a decrease of tdTomato red expression was observed in both control and rapamycintreated mice from days 2 to 11 with only scattered red punctate particles remaining in both control and rapamycintreated mice (Fig. 1f, i ). Systematic quantification of red labelled cells confirmed histological impressions, demonstrating a significant increase in the number of red cells with rapamycin treatment compared with controls (P,0.01) and a significant main effect of time (P,0.001) (Fig. 1b) .
Since the ependyma and underlying subventricular zone are known to contain neural stem cells (Johansson et al., 1999) , we determined whether the cells expressing the viral protein are potentially stem cells. We utilized nestin, an intermediate filament protein, as a marker for neural progenitor cells (Lendahl et al., 1990) , although it also stains other cell types such as pericytes and periendothelial cells in brain parenchyma (Alliot et al., 1999) . Brain sections were immunohistochemically stained with antinestin antibody (GenScript rabbit polyclonal antibody, biotinylated goat anti-rabbit secondary and streptavidinDyLite 488), counterstained with DAPI, and examined for tdTomato red expression colocalized with nestin staining.
Immunohistochemical staining revealed a population of nestin-positive cells lining the lateral ventricles of all mice, some with radial glia-like processes extending away from the ventricle, as described previously (Gubert et al., 2009) . In mice inoculated with MYXV-Red, tdTomato red expression was observed in a subpopulation of the nestin-positive cells at day 2 post-inoculation (Fig. 2a) , demonstrating that myxoma virus can enter and express proteins in certain nestin-positive cells. Not all nestinpositive cells were positive for tdTomato red protein, yet most red fluorescent cells appeared to be nestin positive. At day 4 post-inoculation there were fewer nestin-positive cells expressing tdTomato red (Fig. 2b) , and by day 11 post-inoculation nestin-positive cells remained but were no longer red (Fig. 2c) .
We found that a subset of cells in the ventricular zone transiently express viral protein following intraventricular injection, lasting up to 11 days, and that the cells that express protein encoded by MYXV-Red are a population of nestin-positive cells. Next, we determined whether these cells are killed by the virus. Nestin-positive periventricular neural stem cells may be involved in tissue regeneration (Wiese et al., 2004) . Loss of stem cells in the brain could therefore have unforeseen consequences, so it is important to determine whether this population remains viable after MYXV-Red inoculation. We therefore determined whether these cells are effectively lysed by the virus or if the virus is successfully cleared without major loss of neural stem cells.
Histological observation of DAPI and H&E stained sections revealed a mild to moderate amount of residual mononuclear inflammation at 11 days post-injection, but no necrosis or other cellular damage was observed and the ependyma remained intact (Fig. 1c, f, i) . To confirm the impression that ependymal cells were not killed by MYXVRed, terminal deoxynucleotidyltransferase dUTP nick-end labelling (TUNEL) staining was performed to detect apoptosis in the ventricular area at the peak of tdTomato expression. Since the virus attracts a neutrophil infiltrate into the brain, and at least a portion of neutrophils are expected to be undergoing apoptosis, sections were doublestained with an antibody against a neutrophil marker (myeloid differentiation antigen Ly-6G/C, GR-1). Immunohistochemical analysis by confocal microscopy revealed only a small population of apoptotic cells in the ventricular zone. Only a handful of these apoptotic cells also expressed tdTomato red (Fig. 3) . A small number of apoptotic cells were GR-1 positive. Importantly, the vast majority of tdTomato red-positive cells did not appear to be apoptotic and only a small number of any cells were apoptotic at 2 days after virus inoculation. At 4 days post-injection, no apoptotic cells were present and no apoptotic cells were present in the same area in uninoculated brain tissue (data not shown). Studies have shown that many neurotropic viruses preferentially infect ependymal cells and cells of the subventricular zone, particularly those with a neural progenitor cell phenotype, including herpes simplex virus (Braun et al., 2006) , murine cytomegalovirus (Kawasaki et al., 2002) and mumps virus (Takano et al., 1999) . Tada et al. (2005) reported the use of adenovirus as a vehicle for gene transfer into murine ependymal cells. Infection by this virus has been shown to cause ventricular dilation accompanied by diffuse periventricular lymphocyte infiltration and histologically evident loss of ependymal cells from the ventricular wall. In contrast to the histological evidence for loss of ependymal cells with adenovirus, in the present study we saw no evidence of loss of ependymal cells with MYXV-Red. A strain of attenuated replicationcompetent herpes simplex virus, G207, has been shown to be efficacious in treating gliomas, meningiomas and metastatic breast cancer in the brain. However, less attenuated strains caused excessive weight loss and clinical illness in a murine model and loss of ependymal cells and hydrocephalus was present even in the most attenuated strains (Sundaresan et al., 2000) . This is also in contrast to the present effects on periventricular cells by myxoma virus, as we saw no evidence of ependymal cell loss upon histological examination and our mice experienced no weight loss or other symptoms indicative of clinical illness (lethargy, etc.) . In addition, the virally derived protein expression was transient, lasting less than 11 days, even upon treatment with the drug rapamycin. Infiltrating neutrophils represented a portion of the apoptotic cells observed, and very few apoptotic cells around the ventricle expressed tdTomato. A specialized region of the ependyma, the choroid plexus, was also observed to be somewhat susceptible to myxoma virus entry and protein expression, but again this was transient and only very few cells were observed to be apoptotic (Fig. 3) .
In summary, myxoma virus, similar to other viruses, demonstrates a tropism for a small population of cells lining the ventricle that are phenotypically similar to neural stem cells. The expression of MYXV-Red encoded protein in normal ependymal cells was transient and this cell population remained stable over time with no evidence of virus-induced cell death. No accompanying symptoms such as weight loss or lethargy were observed. We have observed a similar safety profile when myxoma virus is injected into the brain parenchyma with no evidence of productive infection or tdTomato red expression in parenchymal cells. Therefore, intracranial injection of myxoma virus appears to be safe for use as a therapeutic agent and a gene delivery vehicle for preclinical studies of brain tumour therapy. Our results warrant special attention to ependymal cells if similar treatments proceed to clinical trials. 
